[go: up one dir, main page]

NO20084047L - Forbedrede anti-tumor behandlinger - Google Patents

Forbedrede anti-tumor behandlinger

Info

Publication number
NO20084047L
NO20084047L NO20084047A NO20084047A NO20084047L NO 20084047 L NO20084047 L NO 20084047L NO 20084047 A NO20084047 A NO 20084047A NO 20084047 A NO20084047 A NO 20084047A NO 20084047 L NO20084047 L NO 20084047L
Authority
NO
Norway
Prior art keywords
cancer
improved anti
tumor treatments
combinations
treatment
Prior art date
Application number
NO20084047A
Other languages
English (en)
Other versions
NO342012B1 (no
Inventor
Glynn Thomas Faircloth
Pablo Manuel Aviles Marin
Doreen Lepage
Jesus San Miguel Izquierdo
Atanasio Pandiella
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20084047L publication Critical patent/NO20084047L/no
Publication of NO342012B1 publication Critical patent/NO342012B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Luminescent Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Den foreliggende oppfinnelsen er relatert til kombinasjoner av aplidin eller aplidin analoger med andre antitumor midler, og anvendelsen av disse kombinasjonene i behandlingen av cancer, spesielt i behandlingen av lunge cancer, bryst cancer, kolon cancer, prostata cancer, nyre cancer, melanom, multippel myelom, leukemi og lymfom.
NO20084047A 2006-02-28 2008-09-23 Forbedrede antitumorale behandlinger NO342012B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81360606P 2006-02-28 2006-02-28
PCT/US2007/062936 WO2007101235A2 (en) 2006-02-28 2007-02-28 Improved antitumoral treatments

Publications (2)

Publication Number Publication Date
NO20084047L true NO20084047L (no) 2008-11-25
NO342012B1 NO342012B1 (no) 2018-03-12

Family

ID=38459806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084047A NO342012B1 (no) 2006-02-28 2008-09-23 Forbedrede antitumorale behandlinger

Country Status (23)

Country Link
US (1) US8258098B2 (no)
EP (1) EP2029155B1 (no)
JP (2) JP5393159B2 (no)
KR (2) KR101512503B1 (no)
CN (1) CN101389347B (no)
AU (1) AU2007220050B2 (no)
CA (1) CA2643238C (no)
CY (1) CY1117722T1 (no)
DK (1) DK2029155T3 (no)
ES (1) ES2575518T3 (no)
HR (1) HRP20160646T1 (no)
HU (1) HUE028055T2 (no)
IL (1) IL193094A (no)
ME (1) ME02450B (no)
MX (1) MX2008010999A (no)
NO (1) NO342012B1 (no)
NZ (1) NZ571043A (no)
PL (1) PL2029155T3 (no)
PT (1) PT2029155E (no)
RS (1) RS54928B1 (no)
RU (1) RU2481853C2 (no)
SI (1) SI2029155T1 (no)
WO (1) WO2007101235A2 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003514025A (ja) * 1999-11-15 2003-04-15 ファルマ・マール・ソシエダード・アノニマ ガンのアプリジン治療
RU2481853C2 (ru) 2006-02-28 2013-05-20 Фарма Мар, С.А. Улучшенные способы лечения опухолей
WO2008135793A1 (en) * 2007-05-04 2008-11-13 Pharma Mar S.A. Combination of aplidine and carboplatin in anticancer treatments
US20100240595A1 (en) * 2007-10-19 2010-09-23 Pharma Mar ,S.A. Improved Antitumoral Treatments
RU2010140890A (ru) * 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные способы противоопухолевого лечения
RU2010140888A (ru) * 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные противораковые терапии
US9226913B2 (en) 2010-01-05 2016-01-05 Celgene Corporation Methods of treating cancer using a combination of an immunomodulatory compound and an artemisinin or a derivative thereof
PL2786754T3 (pl) * 2010-11-12 2019-07-31 Pharma Mar S.A. Leczenie skojarzone inhibitorem mitozy
JP6116482B2 (ja) * 2010-12-01 2017-04-19 ニーキ ファーマ インコーポレイテッド ガリウム錯体を用いる併用療法
HRP20182183T1 (hr) * 2011-11-09 2019-02-22 Bristol-Myers Squibb Company Liječenje hematoloških maligniteta sa anti-cxcr4 antitijelom
KR101369936B1 (ko) * 2011-12-28 2014-03-06 연세대학교 산학협력단 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물
RU2547999C1 (ru) * 2013-10-28 2015-04-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения аденогенного местно-распространенного рака нижнеампулярного отдела прямой кишки
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
EP3895733A4 (en) * 2018-12-14 2022-03-02 Konica Minolta, Inc. METHOD OF PREDICTING THE ARRIVAL OF A DRUG WITHIN DISEASED TISSUE
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
DE3684868D1 (de) * 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
ATE245435T1 (de) 1996-10-24 2003-08-15 Univ Illinois Totalsynthese des amino hip analogen von didemnin a
WO1998017275A1 (en) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Semi-synthetic studies toward didemnin analogues
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
DE69840497D1 (de) * 1997-05-07 2009-03-12 William J Crumb Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
RU2266734C2 (ru) * 1999-05-13 2005-12-27 Фарма Мар, С.А. Композиции и применение ет743 для лечения злокачественных опухолей
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
JP2003514025A (ja) * 1999-11-15 2003-04-15 ファルマ・マール・ソシエダード・アノニマ ガンのアプリジン治療
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
PL358579A1 (en) * 2000-04-07 2004-08-09 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CZ2003993A3 (cs) * 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
AU2001294024C1 (en) 2000-10-12 2006-11-23 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
US20040047807A1 (en) 2001-01-24 2004-03-11 Dominik Meyer Use of neurotoxic substances in producing a medicament for treating joint pains
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
MXPA05009742A (es) * 2003-03-12 2006-05-25 Dana Farber Cancer Inst Inc Aplidina para tratamiento de mieloma multiple.
NZ541634A (en) * 2003-03-12 2008-08-29 Pharma Mar Sa Improved antitumoral treatments
US8030279B2 (en) 2003-03-21 2011-10-04 The Trustees Of The University Of Pennsylvania Tamandarin analogs and fragments thereof and methods of making and using
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
RU2481853C2 (ru) 2006-02-28 2013-05-20 Фарма Мар, С.А. Улучшенные способы лечения опухолей
DE102006061344A1 (de) * 2006-12-22 2008-06-26 Robert Bosch Gmbh Kupplungshydraulikkreis
WO2008080956A1 (en) 2006-12-29 2008-07-10 Pharma Mar, S.A. Prognostic molecular markers for the cancer therapy with aplidine
WO2008135793A1 (en) 2007-05-04 2008-11-13 Pharma Mar S.A. Combination of aplidine and carboplatin in anticancer treatments
US20100240595A1 (en) * 2007-10-19 2010-09-23 Pharma Mar ,S.A. Improved Antitumoral Treatments
WO2010029158A1 (en) 2008-09-12 2010-03-18 Pharma Mar, S.A. Aplidine in the treatment of chronic myeloproliferative disorders

Also Published As

Publication number Publication date
CN101389347A (zh) 2009-03-18
DK2029155T3 (en) 2016-08-01
US20090246168A1 (en) 2009-10-01
CA2643238A1 (en) 2007-09-07
JP2009528379A (ja) 2009-08-06
AU2007220050A1 (en) 2007-09-07
HUE028055T2 (en) 2016-11-28
NZ571043A (en) 2012-06-29
EP2029155A2 (en) 2009-03-04
IL193094A (en) 2015-06-30
HK1127294A1 (zh) 2009-09-25
JP2013199500A (ja) 2013-10-03
IL193094A0 (en) 2011-08-01
HRP20160646T1 (hr) 2016-08-12
CA2643238C (en) 2016-05-03
KR20140101014A (ko) 2014-08-18
KR20080105123A (ko) 2008-12-03
RS54928B1 (sr) 2016-10-31
NO342012B1 (no) 2018-03-12
EP2029155A4 (en) 2009-10-14
WO2007101235A2 (en) 2007-09-07
ME02450B (me) 2016-09-20
JP5393159B2 (ja) 2014-01-22
ES2575518T3 (es) 2016-06-29
EP2029155B1 (en) 2016-04-13
KR101512503B1 (ko) 2015-04-15
SI2029155T1 (sl) 2016-06-30
PL2029155T3 (pl) 2016-09-30
CY1117722T1 (el) 2017-05-17
AU2007220050B2 (en) 2013-08-29
US8258098B2 (en) 2012-09-04
CN101389347B (zh) 2013-03-27
MX2008010999A (es) 2008-09-08
WO2007101235A3 (en) 2008-04-03
RU2481853C2 (ru) 2013-05-20
PT2029155E (pt) 2016-06-17
RU2008138560A (ru) 2010-04-10

Similar Documents

Publication Publication Date Title
NO20084047L (no) Forbedrede anti-tumor behandlinger
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
PH12022551486A1 (en) Compounds and methods for the targeted degradation of androgen receptor
IL258880A (en) Diarylhydantoin compounds
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
MA32900B1 (fr) Compose d'aminopyrazole
GB0505781D0 (en) Chemical compounds
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2024000614A (es) Anticuerpos anti-fgfr2 combinados con quimioterapia para el tratamiento del cancer.
WO2008015383A3 (en) Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
MY204673A (en) Humanized anti-sirp antibodies
TNSN08401A1 (en) Methods of treating diagnosing or detecting cancer
FR2945210B1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
MX2025003936A (es) Combinacion de talazoparib y enzalutamida en el tratamiento del cancer de prostata metastasico resistente a la castracion
MX2009010954A (es) Actividad antitumoral de temsirolimus en cancer celular renal papilar.
NZ593169A (en) Anticancer compounds
EA201070295A1 (ru) Лечение рака легких
ATE443138T1 (de) Hemmung der expression von spag9 mit sirnas
EA201291268A1 (ru) Противоопухолевая комбинация, содержащая омбрабулин, производное таксана и производное платины
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer